VIR – vir biotechnology, inc. (US:NASDAQ)
Stock Stats
News
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Vir Biotechnology (VIR) had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus [Yahoo! Finance]
Vir Biotechnology to Participate in Upcoming Investor Conferences
Vir Biotechnology (VIR) had its "outperform" rating reaffirmed by Leerink Partners.
Form 8-K Vir Biotechnology, Inc. For: Apr 07
Form 4 Vir Biotechnology, Inc. For: Apr 06 Filed by: De Backer Marianne
Form 144 Vir Biotechnology, Inc. Filed by: De Backer Marianne
Form 4 Vir Biotechnology, Inc. For: Apr 01 Filed by: SATO VICKI L
Form SCHEDULE 13G/A Vir Biotechnology, Inc. Filed by: VANGUARD GROUP INC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.